Health ❯ Healthcare

Patient Care

Treatment Options Hospitalization Emergency Services Chronic Conditions Quality of Life Chronic Illness Diagnosis Chronic Illness Management Access to Care Treatment Efficacy

FDA Approves Oral Wegovy, First GLP-1 Pill for Obesity, With U.S. Launch in January

The once-daily semaglutide tablet showed mid‑teens weight loss in trials and is set to roll out with a $149 starter offer.

FDA Approves First Oral GLP-1 Weight-Loss Drug With Wegovy Pill Launching in January

GLP-1 Drugs Are Reshaping U.S. Food Purchases, Cornell Study Finds

Barry Manilow, 82, Diagnosed With Early Lung Cancer, Postpones January Shows

Longitudinal Study Finds One in Four U.S. Adults Faces Unaffordable Care or Skips Treatment

Donor Support Expands Santa's Visit at Teddy's Place NICU in Annapolis

Stories older than 24h

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Mount Sinai's NutriSighT Predicts Underfeeding Risk in Ventilated ICU Patients

FDA Grants Accelerated Approval to Subcutaneous Lunsumio VELO for Relapsed Follicular Lymphoma

Large Swedish Study Finds ARBs Sustain the Best Long-Term Adherence in Hypertension

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

Crown Princess Mette-Marit Begins Evaluation for Possible Lung Transplant After Health Declines

UVA Board Unanimously Names Darden Dean Scott Beardsley President

Risk-Based Breast Cancer Screening Matches Annual Mammograms in JAMA Trial

Norovirus Surge Triggers Chicago-Area Remote Schooling as Hospitals and Data Show Spikes

Children's Hospital Colorado Performs Region's First Pediatric Heart–Liver Transplant

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

FDA-Approved AI Tool Shows Promise for Faster Autism Diagnosis in Rural Primary Care